CNBC Stock Blog
- Buy These 'Competitively Positioned' Stocks: Portfolio Manager
- 5 Stocks That Benefit from Health Care Legislation: Analysts
- 9 Stocks That Play Rising Water Costs: Strategists
- Gold Prices Can Double in 3 Years: Portfolio Manager
- Rally Could 'Have Some Legs in 2010': Market Strategist
- Expect a 'Square Root-Shaped' Recovery: Chief Investor
- HP to Feed on Enterprise Spending Next Year: Tech Analyst
- How Stock Investors Can Play Holiday Travel
- 3 Growth Opportunities in Tech: Analyst
- Prep Your Portfolio for Next Week: Stock Pickers
MOST SHARED
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- US Home Prices Up 5th Month, 2nd Straight Quarter
- China Eastern to Complete Shanghai Air Buy by End '09
- Gold Will Collapse Like Oil Did in 2008: Charts
- Wave of Debt Payments Facing US Government
- Weak Dollar Is Golden for Mining Companies
- Revised GDP Reading Puts Growth at 2.8%; Inflation Tame
- FDIC Insurance Fund Falls to Negative $8.2 Billion
- GM's Plan to Sell Saab Unit To Swedish Firm Falls Apart
- The Lloyd's Prayer, Leggo My Eggo, Plate Hate & Your Emails
- Buy These 'Competitively Positioned' Stocks: Portfolio Manager
- Behind The Scenes With Warren Buffett
- 'Why the American Consumer Will Keep on Buying No Matter What'
- On Assignment: Europe & Asia
- The L.A. Extravaganza: A Test for Auto Shows
- 8 Stocks That Could Gain With Rising GDP
- 5 Stocks That Benefit from Health Care Legislation: Analysts
- Can Murdoch Help Bing Challenge Google and Shift the Content Equation?
- Consumer Confidence Improves But Still Shaky
- US Home Prices Up 5th Month, 2nd Straight Quarter
- Revised GDP Reading Puts Growth at 2.8%; Inflation Tame
- FDIC Insurance Fund Falls to Negative $8.2 Billion
- Ron Paul's Plan to Audit Fed a 'Serious Attack': Mishkin
- US Economy Mired in 'Form of Depression': Rosenberg
- Strong Banks, Weak Credit: Treasury Rethinks TARP
- Fairfax Lawsuit Keeps Heat on Chanos, SAC's Cohen
- Blog: Behind The Scenes With Warren Buffett
RSS FEED
Text Size 
writer, OptionMonster
Boston Scientific has rallied back to its highest levels since last year's financial crisis and is scheduled to discuss a key defibrillator trial this morning, prompting one large investor to position for a potential decline.
Volume in the September 11 puts climbed to 7,336 against open interest of 2,143 contracts. A large purchase for $0.20 accounted for most of the activity, according to OptionMonster's tracking systems.
Boston Scientific [BSX
Loading...
()
] rose 2.71 percent to close at $11.75 yesterday and is up 6 percent in the last month. The heart device company will present final results for the trial of its MADIT-CRT defibrillator at 8 a.m. ET today. On June 24, management said the device met its primary endpoint by reducing heart failure.
The puts purchased yesterday will protect against a 6 percent drop in Boston Scientific shares.
___________________________
Options Trading School:
___________________________
Boston Scientific Competes With:
Johnson & Johnson [JNJ
Loading...
()
]
Medtronic [MDT
Loading...
()
]
St. Jude Medical [STJ
Loading...
()
]
___________________________
___________________________
David Russell is a reporter and writer for OptionMonster.
___________________________
Data is a real-time snapshot *Data is delayed at least 15 minutes